Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Study of Latozinemab in Neurodegenerative Disease
2023-506805-20-01Phase 3Completed
- Sponsor
- Alector
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of latozinemab in Neurodegenerative disorders (NDDs), sponsored by Alector. Primary endpoints: Number of participants receiving latozinemab and Duration of treatment. Started Aug 2024; status: completed.
02
Drugs
latozinemab
03
Conditions
Neurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on 2023-506805-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506805-20-01.